Organization
Norway
4 abstracts
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.Org: Haukeland University Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Bergen, Norway, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway,
Abstract
A MULTICENTER RANDOMIZED STUDY IN EARLY RHEUMATOID ARTHRITIS TO COMPARE ACTIVE CONVENTIONAL THERAPY VERSUS THREE BIOLOGICAL TREATMENTS: 24 WEEK EFFICACY RESULTS OF THE NORD-STAR TRIALOrg: Denmark, Finland, Iceland, Netherlands Cancer Institute, Norway,
Abstract
BASELINE AUTOANTIBODY PROFILE AS A RISK FACTOR FOR DAMAGE DEVELOPMENT IN SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Dept. of Rheumatology, Copenhagen University Hospital at Hvidovre and Gentofte, Hvidovre and Gentofte, Dept. of Rheumatology, Copenhagen University Hospital at Hvidovre and Herlev, Hvidovre and Herlev, Denmark, Institute of Clinical Medisine, Dept. of Biochemistry, Charite University Hospital, Berlin, Germany, Institute of Medical Biology, Chinese Academy of Medical Sciences, University of Tromsö,